research Role of serum androgens and prostate-specific antigen levels in males with androgenetic alopecia
Higher serum androgens contribute to male pattern baldness.
Search
for
Sort by
Research
540-570 / 1000+ results
research Association between degrees of alopecia and prostate specific antigen level in men with androgenetic alopecia
No link found between hair loss severity and PSA levels in men.
research P152 : Association between degrees of alopecia and prostate specific antigen level in men with androgenetic alopecia
No link between hair loss severity and PSA levels in men.
research Faculty Opinions recommendation of Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis.
Hair loss at the top of the head is linked to prostate cancer, but other types of hair loss are not.
research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor
Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
research 5α-reductase activity in the prostate
Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content*
A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
research The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
research Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
Tamsulosin for enlarged prostate may increase the risk of severe low blood pressure, especially when starting or restarting the medication.
research Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
research Association of Benign Prostatic Hyperplasia with Male Pattern Baldness
Men with enlarged prostates often have more severe baldness.
research Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy
Some men's prostate tissues have low enzyme levels due to genetic changes, possibly affecting treatment for prostate enlargement.
research Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
Taking 5-α reductase inhibitors for prostate enlargement or hair loss does not significantly raise the risk of erectile dysfunction.
research Relationship Between Male Pattern Baldness and the Risk of Aggressive Prostate Cancer: An Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.
research Endocrinology of the Aging Prostate: Current Concepts
Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.
research Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride
Dutasteride does not impair mental function in elderly men with enlarged prostate.
research Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction
Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.
research Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia
Finasteride worsens erectile dysfunction and lowers testosterone in men with enlarged prostates, unlike tamsulosin.
research Antiandrogen Drugs Lower Serum Prostate-Specific Antigen (PSA) Levels in Hirsute Subjects: Evidence That Serum PSA Is a Marker of Androgen Action in Women1
Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.
research α-spinasterol from Melandrium firmum attenuates benign prostatic hyperplasia in a rat model
α-spinasterol from Melandrium firmum can help reduce prostate enlargement.
research Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature
Finasteride helps with prostate symptoms but may cause sexual side effects.
research Oral administration of low-dose bisphenol A promotes proliferation of ventral prostate and upregulates prostaglandin D2 synthase expression in adult rats
Low doses of BPA can increase prostate growth and change hormone levels in adult rats.
research Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study
Finasteride does not prevent bladder cancer.
research Exploring the Inhibitory Potential of Phytosterols β-Sitosterol, Stigmasterol, and Campesterol on 5-Alpha Reductase Activity in the Human Prostate: An In Vitro and In Silico Approach
Phytosterols may help manage prostate issues but are less effective than synthetic drugs.
research Docking and Molecular Dynamics Identify Leads against 5 Alpha Reductase 2 for Benign Prostate Hyperplasia Treatment
New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
research Therapeutic Considerations Related to Finasteride Administration in Male Androgenic Alopecia and Benign Prostatic Hyperplasia
Finasteride can still be used for hair loss with careful consideration of side effects and patient information.
research Benign prostatic hyperplasia, metabolic syndrome and androgenic alopecia: Is there a possible relationship?
People with early hair loss may have a higher chance of enlarged prostate and metabolic syndrome, so they should be checked for urinary and metabolic issues.
research The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.
research An observational study of the association between androgenetic alopecia and size of the prostate
The conclusion is that more hair loss (androgenetic alopecia) is linked to larger prostate size, suggesting hair loss could be an early sign of benign prostatic hyperplasia.
research 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia
Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.